Patent Strategies and Competition Law in the Pharmaceutical Sector: Implications for Access to Medicines
661 - 667
European Intellectual Property Review
MetadataShow full item record
Potentially anti-competitive practices, such as reverse payment agreements and strategic patenting, risk allowing pharmaceutical companies to block the entry of generic and innovative medicines, stifling competition and harming consumers. Such practices create particular challenges for developing countries. Policy coherence between the IP system and competition law must be strengthened in order to promote innovation and access to health technologies.
AuthorsMATTHEWS, DN; Gurgula, O
- Department of Law 
Showing items related by title, author, creator and subject.
Gee, Lim Heng (1996)Prior to 1986, Malaysia had a system whereby patents issued in the United Kingdom could be registered in Malaysia. On registration, the patent owner would have privileges and rights as those conferred by the issue of ...
Chung, Shang-pei (Queen Mary University of London, 2012-10)The reconciliation of patents within the Taiwanese Law of Things has received negligible attention from legal scholars. The primary reason for this is the hesitation, by courts and scholars alike, to construct a new property ...
DRAHOS, P; Cheng, W (Max-Planck-Institut für Immaterialgüter- und Wettbewerbsrecht, 2017-12-05)In 2011 China’s patent office received more patent applications than any other patent office in the world. While explanations for this patent surge focus on some relevant factors such as the use of subsidies for application ...